RxDoctor Payments Data

Ali Husain, DO

Family Medicine · San Diego, CANPI 1790073419

Payments from drug & device makers

$1,021in general payments, 2019–2025

Across 38 payments — averaging $26.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$487
  • Johnson & Johnson$150
  • Boehringer Ingelheim$140
  • Sunovion Pharmaceuticals Inc.$54
  • GSK$50
  • Lilly USA, LLC$29
  • plus $110 from 5 others

What the payments were for

  • Food & beverage$1,021100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,021 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$146,935
Medicare patients
368
Services billed
1,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$88,432
OzempicSemaglutide47$56,173
BiktarvyBictegrav/Emtricit/Tenofov Ala13$52,791
JardianceEmpagliflozin33$47,665
XareltoRivaroxaban22$22,316
MyrbetriqMirabegron18$15,662
Spiriva HandihalerTiotropium Bromide17$10,338
Spiriva RespimatTiotropium Bromide12$7,138
Arnuity ElliptaFluticasone Furoate14$5,380
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,718
Atorvastatin Calcium343$3,708
Levothyroxine Sodium245$3,588
Albuterol Sulfate HfaAlbuterol Sulfate62$2,680
Duloxetine Hcl50$2,622
Rosuvastatin Calcium181$2,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$487$56,17347 claims
Boehringer IngelheimJardiance, Spiriva Respimat$140$54,80245 claims
Johnson & JohnsonXarelto$150$22,31622 claims
Astellas Pharma US IncMyrbetriq$14$15,66218 claims
GSKArnuity Ellipta$50$5,38014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →